Tag Pharma Stocks

Cipla Ltd
Cipla Share Price Under Pressure Despite Strong Growth: Smart Investment or Risky Bet?

Business and Industry Overview: 

Cipla Ltd is a large medicine company from India. It started in the year 1935. The founder was Dr. Khwaja Abdul Hamied. The company is based in Mumbai. Cipla has been working for more than 80 years. Its goal is to care for life. The company makes good-quality medicines. These medicines are also low-cost. Cipla wants to help people who cannot afford expensive treatment. That is why many doctors and patients trust Cipla. People in over 80 countries use Cipla’s medicines. Cipla makes over 1,500 products. These products come in more than 50 types or dosage forms. Cipla’s medicines help with many health problems. These include asthma, heart disease, diabetes, arthritis, depression, and HIV/AIDS. Cipla has 47 factories around the world. It is growing fast in India, South Africa, and the United States. It is also growing in other developing countries. The company wants to make healthcare easy and affordable for more people. One of Cipla’s biggest moments was in 2001. At that time, many people in Africa could not get HIV/AIDS medicine. Cipla offered a triple therapy for HIV/AIDS. It costs less than 1 dollar a day. This helped many poor people stay alive. It also changed how the world saw healthcare. It showed that life-saving medicines can be made cheap and accessible. Cipla is also a responsible company. It cares for the communities where it works. It works with global health groups and other partners. People like Cipla because of its humanitarian work. Helping people is always Cipla’s main purpose. Cipla will keep working to save lives. It will continue to offer safe, good, and affordable medicines to the world. 

Latest Stock News: 

Cipla Ltd is a big company in the medicine industry. Today, its stock price went very low. It reached a 52-week low of ₹1,310.05. In the last 2 days, the stock price fell by 7.57%. Today, it opened with a loss of 7.45%. Even with this fall, Cipla did better than other pharma companies. The full pharma sector fell by 3.8%. Cipla’s stock is now below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This means the stock is in a downtrend. The price is going down again and again. In the past year, Cipla’s stock went down by 4.23%. At the same time, the Sensex (market index) fell by 2.46%. So, Cipla did worse than the overall market. But the company is still doing well. It has shown good profit growth. Its operating profit is growing at 21.54% every year. Cipla gave positive results in the last 7 quarters. That means Cipla has been doing well for almost 2 years. Cipla also has low debt. It is not borrowing too much money. The ROCE (Return on Capital Employed) is 22.24%. This number is good. It shows Cipla is using its money in a smart way. But there is one problem. The promoters (main owners of the company) sold some of their shares. Their holding went down by 1.73%. This may show that they are less confident about the future. Right now, Cipla’s stock is facing mixed signals. The company is financially strong, but the market is not happy. Investors are watching closely. 

Potentials: 

Cipla Ltd. has strong plans for the future, focusing on growth, innovation, and global expansion. The company wants to grow in big markets like the United States by launching new medicines and buying or partnering with other companies, especially in complex generics and specialty drugs. In India, Cipla plans to reach more people by moving into smaller cities (Tier 2 to Tier 6). In Africa, Cipla is focusing on big cities and helping people who don’t have easy access to healthcare. The company also spends a lot on research and development (R&D) — around ₹1,571 crore every year, which is 6% of its income — to make new and better medicines, including for respiratory problems and injections.  It is also working on bringing new anti-diabetes medicines to India by teaming up with big global firms. On the environment side, Cipla has big goals. By December 2025, it wants to make its India factories carbon neutral, water neutral, and send zero waste to landfills. It is using more renewable energy to reach these goals. Cipla is also planning to join the obesity drug market in India, which is growing fast. It may work with companies like Eli Lilly and is also making its versions of these medicines. All these steps show that Cipla is working hard to grow, help more people, and stay strong in the global medicine market. 

Analyst Insights: 

  • Market capitalisation: ₹ 1,11,806 Cr. 
  • Current Price: ₹ 1,384 
  • 52-Week High/Low: ₹ 1,702 / 1,274 
  • P/E Ratio: 22.5 
  • Dividend Yield: 0.96%
  • Return on Capital Employed (ROCE):22.8 % 
  • Return on Equity (ROE):16.8 % 

Cipla Ltd is a strong and stable company. Its profit increased from ₹1,545 crore in FY13 to ₹4,987 crore in the last twelve months. This shows that Cipla is growing well. The Earnings Per Share (EPS) also went up from ₹19.24 to ₹61.79. This means the company is giving better returns to its shareholders. The company’s operating profit margin (OPM) improved from 22% in December 2023 to 28% in December 2024. This shows Cipla is managing its costs better and earning more from its core business. The company has very little debt. This makes it safe during tough times and helps it to invest more in future growth. Cipla’s Return on Capital Employed (ROCE) is 22.8%, and Return on Equity (ROE) is 16.8%. These numbers show that Cipla is using its money and capital in a good way. Cipla is a top company in India for respiratory medicines. It also sells complex generic and special medicines in India and other countries like the US and South Africa. It is investing in digital health and working with tech health platforms. This will help Cipla grow more in the future. The company gives regular dividends. Its dividend payout ratio is 22%, which shows strong cash flow and care for shareholders. Sales growth was slow in the past five years, and promoter holding has gone down. But the company is still strong with a good balance sheet and smart plans. Because of all these reasons, Cipla is a good stock for long-term investors. So, the recommendation is to buy. 

Marksans Pharma Ltd
Marksans Pharma Gains 4% on Australian Approval for Goa Facility & Growth Potential

Business and Industry Overview:  

Marksans Pharma Ltd. is a medical company based in Mumbai, India. It makes and sells medicines in over 50 countries, including the U.S., U.K., Europe, and Australia. The company makes two types of medicines—OTC medicines that people can buy without a prescription and prescription medicines that need a doctor’s approval. It makes medicines for pain, cough and cold, digestion, heart problems, brain and nerve issues, cancer, diabetes, and infections. Marksans Pharma has modern factories that follow strict quality rules set by health authorities like the US FDA, UK MHRA, and Australian TGA. The company has a research team with 50+ scientists who develop new medicines and improve old ones. It has over 300 medicines, 1,500 product versions (SKUs), and 2,000 employees. Marksans Pharma is one of the top five Indian medicine companies in the U.K. and is growing fast in the U.S. It is working to expand more by entering new markets, making new medicines, and increasing production. The pharmaceutical industry makes medicines. These medicines help people stay healthy. They also treat different diseases. The industry includes research, manufacturing, and selling medicines. India is a big medicine maker in the world. It supplies medicines to over 150 countries. Indian medicines are affordable and of good quality. 

Indian companies make low-cost vaccines. They also make important medicines for diseases like HIV. Many people from other countries come to India for medical treatment. Indian treatment is cheap and advanced. The Indian pharma industry is growing fast. It is expected to be US$ 130 billion by 2030. By 2047, it may reach US$ 450 billion. Indian companies are expanding in the U.S., Europe, and other markets. India has many approved medicine factories. These factories follow high global standards. They are approved by the US FDA, WHO, and other agencies. The government is helping the industry. It is giving money and making new policies. It allows foreign companies to invest in Indian pharma. The Pradhan Mantri Bhartiya Jan Aushadhi Kendras sell cheap generic medicines. The PLI scheme helps India make more medicines. India makes medicines at a low cost. It is cheaper than many other countries. With better technology and strong demand, the Indian pharma industry will keep growing. It will help people all over the world. 

Marksans Pharma is a big medicine company. It sells good and affordable medicines. It sells in over 50 countries. It is among the top five Indian pharma companies in the U.K. The company makes two types of medicines. One is an Over-the-Counter (OTC) medicine. The other is prescription medicine. These medicines help in pain relief, cold, digestion, cancer, diabetes, and infections. Marksans Pharma has modern factories. These factories follow global health standards. Marksans Pharma has a strong research team. More than 50 scientists work there. They make new and better medicines. The company makes medicines at a low cost. This is because it is produced in India. Marksans Pharma has a fast and strong supply chain. This helps in quick and safe delivery. The company is growing fast. It is expanding in the U.S. and Europe. It is also using new technology. This helps in making better medicines. But it has low prices. It has good quality. It has strong research. It has a global presence. This makes it a strong player. The company is ready for more growth in the future. 

Latest Stock News: 

Marksans Pharma is growing in many countries. It’s a UK-based company, Relonchem Ltd, that got approval from the UK MHRA. Now, it can sell Baclofen 10 mg Tablets in the UK. This medicine is used to treat muscle spasms. It helps people with multiple sclerosis and spinal injuries. The company also got approval from the Australian TGA. This approval is for its Goa factory. Now, the factory can make tablets and hard capsules for Australia. This helps the company expand in the Australian market. Marksans Pharma had good financial results in the third quarter of 2024-25. The company made ₹681.85 crore in sales. It earned ₹138.77 crore profit before tax. This shows strong business growth. There is also a change in the company’s management. Mr. S.R. Buddharaju, an Independent Director, completed his 10-year term. His term ended on March 31, 2025. He is no longer a director. He is also not a member of any Board Committees now. The company thanked him for his work and appreciated his contributions. The company’s share price was ₹221.97 on April 1, 2025. This shows that investors are interested in the company. Marksans Pharma is expanding worldwide. It is following international rules. It is making good profits. It is also managing the company well. 

Potentials: 

Marksans Pharma has big plans for the future. It wants to expand into global markets and launch more medicines in the UK, USA, Australia, and Europe. The company is also entering new countries to grow its business. To increase production, Marksans Pharma is upgrading its factories. It is investing in infrastructure, especially in the newly acquired Teva plant in Goa. This will help the company grab more opportunities in different markets. The company is working on backward integration by filing Drug Master Files (DMFs) for key products. This means controlling the supply chain and reducing dependency on external suppliers. Marksans Pharma has big plans for the UK market. It will file 34 new products in the next two years. These will be high-value medicines with strong profit potential. During a conference call, the company answered questions from analysts and investors. It said it expects double-digit growth in the UK and US markets. Growth will come from new products and better market reach. The company is also focusing on its Over-The-Counter (OTC) business. It plans to grow by acquiring other businesses in strong markets, especially in the EU. Marksans Pharma’s financial growth is strong. Revenue has gone up due to higher sales, better strategies, and good market conditions. Big investors are showing more interest in Marksans Pharma. Foreign Institutional Investors (FIIs) now hold 15.55%, and Domestic Institutional Investors (DIIs) hold 4.76% (as of Dec 2023). This means investors trust the company’s growth. 

Analyst Insights: 

  • Market capitalisation: ₹ 10,466 Cr. 
  • Current Price: ₹ 231 
  • 52-Week High/Low: ₹ 359 / 130 
  • P/E Ratio: 28.4 
  • Dividend Yield: 0.25%
  • Return on Capital Employed (ROCE): 20.6% 
  • Return on Equity (ROE): 16.5% 

Marksans Pharma is working hard to become a top pharmaceutical company. It is focusing on new products, better factories, strong finances, and global growth. It is growing well. Sales reached ₹2,474 Cr in the last year. This is 18% more than the previous year. Profit also increased by 26%. In the last five years, sales grew by 17% every year. Profit grew by 33% every year. This means the company is doing better every year. The company has very little debt. This is good because it does not have to pay a lot of interest. It uses its money well. The Return on Capital (ROCE) is 20.6%. This means the company makes ₹20.6 profit for every ₹100 it invests. The Return on Equity (ROE) is 16.5%. This means it makes ₹16.5 profit for every ₹100 of shareholders’ money. These numbers show good business performance. Big investors are buying more shares. This is a good sign. Foreign investors (FIIs) had 3.46% shares in 2022. Now they have 21.95% shares. Indian investors (DIIs) had 0.47% shares before. Now they have 4.30% shares. This means big investors trust the company. But there is one small worry. Company owners (promoters) had 48.25% shares before. Now they have only 43.87% shares. This means they sold some shares. This is something to watch. Marksans is not too expensive compared to other companies. The P/E ratio is 28.4. The industry average P/E is 36.75. This means Marksans stock is cheaper than many other pharma stocks. The stock gave 61% returns every year in the last three years. This is very high growth. The company is investing money to grow. It is expanding its factory in Goa. It is launching 34 new products in the UK. This can help the company make more sales in the future. One problem is that profit margins are lower. Before, the company had a 25% profit margin. Now, it is only 20%-21%. This means costs have increased. 

Marksans Pharma is a strong company. It is growing well. If you already own the stock, hold it. If you want to buy, wait for a better price.

JB Chemicals & Pharma Ltd
JB Chemicals & Pharma Shares in Spotlight as KKR Plans to Offload 10.2% Stake

Business and Industry Overview: 

J B Chemicals and Pharmaceuticals Ltd (JBCPL) is a leading Indian medicine company. It has been making quality medicines for 47 years. It is one of the top 25 pharmaceutical companies in India. The company makes 350+ medicines for 20+ health problems. These include heart diseases, stomach issues, infections, and pain relief. Some of its famous brands are Rantac (for acidity), Metrogyl (for infections), and Nicardia (for high blood pressure). JBCPL has 5000+ employees. They work in 10 offices across India. JBCPL has 8 modern factories in India. These factories follow strict quality rules set by global health agencies. One of these factories is specialised in making lozenges (medicated throat candies). The company also sells medicines in over 40 countries. Some of its biggest markets are Russia, South Africa, and the U.S. In the last three years, JBCPL has been the fastest-growing pharma company in India. It has grown by launching new medicines, acquiring other brands, and expanding into new countries. The company has a strong financial position. It invests in research, technology, and high-quality production. JBCPL continues to grow and improve healthcare in India and around the world. 

The pharmaceutical industry makes medicines that treat diseases and help people live healthier lives. This industry is growing fast because healthcare needs are increasing. New technology helps companies develop better medicines for different diseases. India is a major player in the global pharmaceutical industry. It is known as the “Pharmacy of the World” because it makes high-quality medicines at affordable prices. India is the world’s largest supplier of generic medicines. Generic medicines are cheaper versions of branded medicines, but work the same. India also produces low-cost vaccines that are used in many countries. One of India’s greatest achievements is providing affordable HIV treatment. This has saved many lives worldwide. India also makes affordable vaccines that help protect people from diseases. Because of this, India is important in global healthcare. India’s pharmaceutical industry is strong because of low manufacturing costs. It costs 30% to 35% less to make medicines in India compared to the US and Europe. Research and development (R&D) costs are also much lower in India—87% less than in developed countries. This helps make medicines affordable for more people. The country has many skilled workers, but their salaries are lower than in other countries, which keeps production costs down. The Indian pharmaceutical market is growing. By 2030, it is expected to be worth $130 billion. By 2047, it could reach $450 billion. The government is helping by providing support to increase production and attract investment. One of the ways it helps is through the Production-Linked Incentive (PLI) scheme. This scheme encourages companies to produce more medicines and create more jobs. The government also helps small pharma companies improve their products through the Strengthening of Pharmaceutical Industry (SPI) Scheme. India makes it easy for foreign companies to invest in the pharmaceutical sector. India allows 100% foreign investment in new pharma projects. Since 2000, India has received $22 billion in foreign investments for pharmaceuticals. This shows that foreign companies trust India’s pharma industry. India’s pharmaceutical companies sell medicines to many countries, including the US and Europe. India has the largest number of USFDA-approved factories outside the US. It also has over 2,000 WHO-GMP-approved factories, meaning the medicines made in India meet high international standards. With the help of the government, low costs, and new technology, India’s pharmaceutical industry will continue to grow and provide affordable medicines to people all around the world. 

JB Chemicals and Pharma Ltd. is a leading company in the medicine industry. It makes a wide variety of medicines for different health problems. The company has modern factories in India. These factories meet international standards, which ensure the quality of their medicines. JB Chemicals sells its products in more than 40 countries. Some of the biggest markets include the US and South Africa. The company can keep production costs low. This allows it to offer high-quality medicines at affordable prices. JB Chemicals focuses on creating new medicines. It also works on improving its existing products. This helps the company stay ahead in the market. The company has strong business partnerships. These partnerships help JB Chemicals reach more customers and grow faster. JB Chemicals is known for its reliable healthcare products. People trust the company for its quality and consistency. The company is growing quickly in both India and abroad. It continues to make medicines that help people live healthier lives. 

Latest Stock News: 

Tau Investment Holdings, a company connected to KKR, sold shares of JB Pharma. They sold 89.83 lakh shares, which is 5.78% of the company. Before selling, they owned 53.66% of JB Pharma. After the sale, their ownership dropped to 47.88%. The shares were sold for ₹1,625 each. This price was slightly lower than the previous day’s price. Even after selling the shares, Tau Investment Holdings still holds a big part of the company. JB Pharma gave 1,700 new shares to employees. These employees had been given stock options as a benefit from the company. They were able to buy these shares at a price. The company received ₹13,32,500 from this process. As a result, the total number of shares in the company increased from 15,56,75,508 to 15,56,77,208. JB Pharma’s manufacturing facility in Gujarat was inspected by the USFDA (U.S. Food and Drug Administration). The inspection took place from March 10 to March 13, 2025. After the inspection, the USFDA found no issues. This means the company is meeting all the required standards for making its products. JB Pharma received a great score for its work on sustainability. The Dow Jones Sustainability Index (DJSI) gave the company a score of 77. The DJSI is a list of the world’s top companies for sustainability. This score shows that JB Pharma is among the best in India and the world for its efforts on the environment and social responsibility. The company has worked on many projects, such as using renewable energy, saving water, reducing waste, and supporting communities. These actions helped JB Pharma earn this high score. 

In summary, JB Pharma is doing well in business. The company is following good quality standards, and it cares about the environment and society. They are also helping their employees and making sure their manufacturing facilities meet the highest standards. 

Potentials: 

JB Pharma wants to become a leader in the medical industry. They plan to make new medicines and improve the ones they already have. The company is focusing on expanding its market reach and selling more products worldwide. They are working hard to grow in international markets. Currently, they are strong in Russia, South Africa, and the United States. They want to expand further into these regions and other places like Europe, Southeast Asia, the Middle East, and Brazil. This will allow more people to use their products. The company is also investing in new factories. They plan to build modern factories to meet the increasing demand for their medicines. They will also upgrade the ones they already have. This will help them keep the quality of their products high. JB Pharma cares about the environment and society. They are working to reduce their impact on the environment by using renewable energy and reducing waste. The company is also focused on helping local communities and being responsible in its operations. In the next two years, JB Pharma plans to increase its revenue by 12-14%. They want to achieve this by growing their chronic medicine products and their contract manufacturing business. This will help the company become more profitable. Each year, JB Pharma plans to launch 6 to 8 new products in India. Some of these products include an iron syrup and a dental probiotic. These products are expected to bring in a lot of revenue for the company. The company also wants to grow its contract manufacturing business. JB Pharma plans to double its revenue from this business in the next 3 to 5 years. They are already one of the top manufacturers of lozenges and sell them in over 40 countries. Additionally, JB Pharma is looking to buy other companies in different areas of healthcare, like heart care, eye care, children’s health, and digestive health. They recently bought some eye care products from Novartis, which will help them expand in this field. JB Pharma is committed to sustainability. They have reduced their energy use by 9% and are now using renewable energy in their operations. The company will continue to focus on sustainability in the future. Overall, JB Pharma’s plans focus on growing their market, improving their products, and being a responsible company that cares for the environment and society. 

Analyst Insights: 

  • Market capitalisation: ₹ 25,352 Cr. 
  • Current Price: ₹ 1,628 
  • 52-Week High/Low: ₹ 2,030 / 1,434 
  • Stock P/E: 39.6 
  • Dividend Yield: 0.75%
  • Return on Capital Employed (ROCE): 24.6% 
  • Return on Equity (ROE): 20.0% 

J.B. Chemicals & Pharmaceuticals Ltd (JBCPL) is a strong company that has been growing well. In the last year, its sales and profits grew by 25%. This means the company is doing better and earning more money. The company makes good profits. It has a profit margin of 26%, which shows it is good at keeping costs low and making money. This is a good sign. JBCPL also gives good returns to investors. It has a return on equity (ROE) of 20%. This means the company is using its money well to make profits. It also gives a good return on capital, which shows it is managing its money smartly. The company has low debt. This is important because it means the company does not owe a lot of money. Low debt makes the company safer and more stable. JBCPL earns money in different ways. 55% of its income comes from selling products in India, while 30% comes from selling products in other countries. It also earns 13% from making products for other companies. This helps the company stay stable. The company pays a small dividend to its investors. Even though the stock is priced higher than its book value, JBCPL’s growth and strong financial health make it a good investment. To sum up, JBCPL is a good company to invest in. It has strong profits, low debt, and is growing well. It is a safe and stable choice for people who want steady growth and small dividends. 

Piramal Pharma Ltd
Piramal Pharma Ltd. surges 3.8%—key Insights and Growth Outlook

Business and Industry Overview: 

Piramal Pharma Limited (PPL) is a global pharmaceutical company. It develops, manufactures, and sells medicines and healthcare products. The company has 17 factories in different countries. It sells its products in over 100 countries. PPL operates in three main areas. Piramal Pharma Solutions (PPS) helps other companies make medicines. Many companies do not have their own factories. They ask PPL to develop and manufacture medicines for them. PPL helps in research, testing, and production. This allows new medicines to reach people faster. Piramal Critical Care (PCC) makes medicines used in hospitals. These include painkillers, anesthesia drugs, and medicines for serious infections. Doctors use these medicines for surgeries and emergency treatments. Hospitals rely on them for intensive care and life-saving procedures. India Consumer Healthcare makes everyday health products. These products can be bought in stores without a prescription. Some popular products include Saridon (for headaches), Lacto Calamine (for skincare), and Polycrol (for digestion problems). Many people in India use these products in their daily lives. PPL has important partnerships and investments. It works with AbbVie Inc., a well-known pharmaceutical company. Together, they have a joint venture called AbbVie Therapeutics India Private Limited. This company makes medicines for eye diseases. It is a leader in ophthalmology in India. PPL has also invested in Yapan Bio Private Limited. This company works on biotechnology and develops new medicines. In October 2020, The Carlyle Group invested in PPL. They bought 20% of the company. This helped PPL expand its research, production, and market reach. PPL is part of the Piramal Group. This group also works in finance and real estate. It operates in over 30 countries. It sells products in more than 100 markets. It has over 10,000 employees from 21 different nationalities. It focuses on making safe and high-quality medicines. It wants to improve healthcare around the world. It aims to make good medicines available to more people. 

The Indian pharmaceutical industry is one of the largest in the world. It provides affordable and high-quality medicines globally. India is known as the “Pharmacy of the World.” It supplies 50% of global vaccine demand. It also meets 40% of generic medicine needs in the U.S. and 25% in the U.K. Indian medicines are exported to more than 200 countries. The country has over 10,500 pharmaceutical manufacturing units. It also has the most U.S. FDA-approved plants outside the U.S. India plays a key role in life-saving drug production. It supplies over 80% of global antiretroviral drugs for HIV/AIDS. Indian medicines are low-cost yet high in quality. Drug manufacturing costs in India are 30-35% lower than in the U.S. and Europe. Research and development (R&D) costs are 87% lower than in developed markets. This makes Indian pharma highly competitive worldwide. The industry is growing fast. It was valued at $50 billion in 2023. It is expected to reach $130 billion by 2030. By 2047, it could touch $450 billion. Growth is driven by strong exports and rising domestic demand. The sector includes generic drugs, vaccines, biosimilars, and biologics. 

The government supports the pharma sector. The Production Linked Incentive (PLI) scheme, worth $2.04 billion, boosts local manufacturing. More funds help MSMEs and pharma clusters improve productivity. The government plans to open 10,500 Pradhan Mantri Bhartiya Jan Aushadhi Kendras by 2025. These stores provide affordable medicines to people. 

Foreign investment in pharma is increasing. India allows 100% FDI in Greenfield pharma projects. Up to 74% FDI is allowed in Brownfield projects through the automatic route. The sector has received $22.52 billion in FDI since 2000. This shows India’s strong position in the global market. The biotechnology sector is expanding. It was valued at $137 billion in 2022. It is expected to grow to $300 billion by 2030. India is among the top 12 biotechnology hubs in the world. The biosimilars market is growing at a 22% annual rate. It could reach $12 billion by 2025. The medical devices industry is also growing. It is valued at $11 billion today. By 2030, it could grow to $50 billion. The government has allocated $120 million in the 2024-25 budget for bulk drug parks. This will boost domestic production. The pharma industry is a key part of India’s economy. It contributes 1.72% to the country’s GDP. It provides jobs to millions of people. Scientists, engineers, and researchers help the industry grow. With strong investments and policies, the Indian pharma sector will expand further. It will continue to improve global healthcare in the coming years. The company is a strong player in the pharmaceutical industry. It makes high-quality medicines at low prices. It sells its products in many countries, including the U.S. and Europe. This helps it grow in global markets. 

Latest Stock News: 

On March 21, 2025, Piramal Pharma Ltd. informed BSE and NSE about the results of the e-voting process related to a postal ballot for the approval of the appointment of Ms. Nathalie Leitch as a Non-Executive, Non-Independent Director of the company. 

The company had issued a notice on February 19, 2025, regarding the remote e-voting process, where members of the company could cast their votes online from February 20, 2025, to March 21, 2025. The resolution was passed with a majority of members voting in favor of the proposal. A total of 1,797 members participated in the e-voting, with 92.21% voting in favor of the resolution and 5.79% voting against it. 

The scrutinizer’s report, which includes the details of the voting process and the final results, was also shared with the company. Based on this scrutiny, the resolution was certified as passed with the requisite majority. The report confirms that the resolution is deemed to be approved as of the last date of voting, March 21, 2025. The company has now made the results and scrutinizer’s report available on its website and on the NSDL platform for public access. 

These developments, along with the positive financial outlook and strategic initiatives discussed earlier, indicate continued confidence in Piramal Pharma’s growth trajectory and leadership decisions, which could influence investor sentiment and share price positively. 

Potentials: 

Piramal Pharma Solutions is expanding its injectables facility in Lexington, Kentucky. The company is investing $80 million for this project. The goal is to more than double the production capacity. Currently, the site produces 104 product batches per year. After expansion, this will increase to over 240 batches. The project is expected to be completed by early 2027. The investment will come from bank loans and internal funds. The expansion will add 24,000 square feet of space. A new laboratory and advanced machinery will also be added. This will help Piramal meet the rising demand for injectable medicines. The injectables market is growing fast. It is expected to reach over $20 billion by 2028. Piramal wants to become a key player in this market. The company has big goals for the future. It plans to double its revenue to $2 billion by 2030. Currently, contract manufacturing brings 58% of its revenue. The company aims to grow this segment even more. Piramal may also benefit from the US Biosecure Act. If passed, this law will stop US agencies from buying biotech equipment from certain Chinese companies. This could create more opportunities for Indian pharma companies. Piramal has already seen more business inquiries since March 2024. Other Indian pharma companies are also expanding. Zydus is increasing research for better medicines. Sun Pharma is working on drugs for obesity and diabetes. Many Indian companies are upgrading their factories to meet global standards. They are also partnering with international firms to expand worldwide. These efforts will help Indian pharma grow and provide better medicines globally. 

Analyst Insights: 

  • Market capitalisation:₹ 28,881 Cr. 
  • Current Price:₹ 218 
  • 52-Week High/Low: ₹ 308 / 119 
  • Stock P/E: 550 
  • Dividend Yield: 0.05%
  • Return on Capital Employed (ROCE): 5.49% 

Piramal Pharma’s stock is trading at ₹218 with a P/E ratio of 550.21, which is extremely high, indicating potential overvaluation. The company’s return on equity (ROE) is very low at just 0.22%, highlighting poor profit generation relative to its equity. Despite having a market cap of ₹28,881 crore, Piramal Pharma’s debt stands at ₹4,710 crore, indicating financial leverage that could be risky. The operating profit margin (OPM) has fluctuated significantly, with a dip to 5.09% in December 2022, showing inconsistent performance. On the positive side, 84% of revenues come from regulated markets like the US, Europe, and Japan, and the company’s customer base has grown to about 500, with a focus on integrated projects that accounted for 40% of new orders in FY24. While the stock’s current valuation and financial metrics raise concerns, its growth prospects in international markets and continued focus on service expansion suggest that investors should hold the stock and monitor future performance for potential improvements. 

Medico Remedies Ltd
Medico Remedies Ltd Stock Plunges 31% – Is It a Buying Opportunity or a Value Trap?

Business and Industry Overview: 

Medico Remedies Ltd (MRL) is a company that makes and sells medicines. It started in 1994 and mainly makes medicines for bacterial infections. The company also makes antibiotics, painkillers, diabetes medicines, heart medicines, antifungal and antimalarial drugs, anti-ulcer medicines, antacids, and vitamins. It also makes creams, gels, syrups, and other medicines for different health problems. The company has a factory in Palghar, where it produces 122.6 million tablets, 36 million capsules, and 0.12 metric tons of dry syrup every month. It uses good-quality ingredients from trusted suppliers to make safe and effective medicines. Harshit Mehta is the Managing Director of Medico Remedies Ltd. He studied pharmacy at the University of Mumbai and also studied family business management at S P Jain Institute in Mumbai. In the third quarter of 2024-2025, the company’s profit grew by 80.69% compared to the same time last year. 

On May 26, 2022, the company moved from a smaller stock market (BSE SME) to a bigger one (BSE and NSE). In 2021, it gave extra shares to investors in a 3:1 ratio and increased its share capital from ₹4.5 crore to ₹17 crore. In 2023, it split one ₹10 share into five ₹2 shares. In 2022, 93% of the company’s money came from selling its own medicines, 3% from selling other goods, and the rest from labor charges, DEPB license transfers, and other income. The company sells its medicines in many countries, including the Dominican Republic (26%), Honduras (20%), Nigeria (12%), the Philippines (8%), Iraq (6%), Mali (6%), Myanmar (6%), and Kenya (4%). 

India’s pharmaceutical industry was worth $42 billion in 2021 and may grow to $130 billion by 2030. India makes the most generic medicines in the world and supplies 60% of all vaccines. Many countries like the US, UK, Canada, and Europe buy medicines from India. In 2023, India’s domestic market was $41 billion, and exports made $25.3 billion. India has 670 US-approved medicine factories, the most outside the US. Major medicine hubs include Mumbai, Hyderabad, Bangalore, and Ahmedabad. The government helps medicine companies by giving money and tax benefits. In 2020, the PLI Scheme gave $2 billion to help Indian companies make better medicines. India is also making more of its own raw materials to depend less on China. Foreign companies can invest fully in new medicine businesses. India’s biotech industry is also growing fast. It made $1.8 billion in 2009-10 and is expected to grow more. With government support, new investments, and low-cost medicines, India’s pharma industry will keep growing. 

Medico Remedies Ltd is a mid-sized pharmaceutical company in India. It makes generic medicines for pain, allergies, diabetes, and more. The company has a WHO-GMP approved factory, which means it follows high-quality standards. It mainly sells in India but also exports some products. Its market value is smaller than big pharma companies, but it is known for quality and affordable medicines. 

Latest Stock News: 

Medico Remedies Ltd’s stock fell by 19.99% to ₹50.7. It was the biggest loser in the BSE ‘B’ group. More shares were traded than usual. In the last month, the stock dropped 31%, and in the past year, it fell 42%. Even after this drop, the stock’s P/E ratio is 47.5x, which is higher than most Indian companies with a P/E below 25x. The company’s earnings are growing, so some investors expect good performance in the future. But if that doesn’t happen, investors may worry about the stock price. 

Potentials: 

Medico Remedies Ltd wants to grow by making good-quality, affordable medicines. The company plans to make more types of medicines for different health problems. It may increase production to make more medicines. It also wants to sell in more countries, which can help it earn more money. The company follows strict quality rules, so more people may trust its products. But there is a lot of competition, and its stock price goes up and down. If it manages money well and grows carefully, it can become a stronger company in the future. 

Analyst Insights: 

  • Market capitalisation: ₹ 469 Cr. 
  • Current Price: ₹ 56.7 
  • 52-Week High/Low:₹ 90.0 / 34.8 
  • P/E Ratio: 53.0 
  • Dividend Yield:0.00 % 
  • Return on Capital Employed (ROCE): 21.3 % 
  • Return on Equity (ROE): 17.2 % 

Medico Remedies has grown its profits well, but its sales growth is slow. The stock price is high compared to earnings and book value, making it expensive. Even though the company makes profits, it does not pay dividends. Promoters have reduced their stake, which may be a concern. Customers are taking longer to pay, affecting cash flow. There are also signs that the company might be adjusting interest costs to look better. It may be better to wait before investing until the stock price drops or the company shows stronger growth. 

Lupin Ltd
Lupin Q3 Results: Profit Soars 39.5% to ₹855 Cr, Revenue Climbs 11%

Business and Industry Overview: 

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, recognised as one of the largest generic pharmaceutical companies globally by revenue. It focuses on areas such as pediatrics, cardiovascular health, anti-infectives, diabetes, asthma, and anti-tuberculosis treatments. The company operates across the entire pharmaceutical value chain, including branded and generic formulations, active pharmaceutical ingredients (APIs), advanced drug delivery systems, and biotechnology products. Lupin’s products reach 70 countries, with a strong presence in advanced markets like the USA, Europe, Japan, and Australia, as well as emerging markets such as India, the Philippines, and South Africa. 

It has a Research Park, located near Pune and Aurangabad, which houses over 1,400 scientists. Lupin’s R&D encompasses the following areas: Generics Research, Process Research, Pharmaceutical Research, Advanced Drug Delivery Systems (ADDS) Research, Intellectual Property Management, Novel Drug Discovery and Development (NDDD), and Biotechnology Research.  

India is the largest global provider of generic drugs and is renowned for its affordable vaccines and generic medications. The Indian pharmaceutical industry is currently ranked third in terms of pharmaceutical production by volume. It has evolved into a thriving sector, growing at a compound annual growth rate (CAGR) of 9.43% over the past nine years. Key segments of the Indian pharmaceutical industry include generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics. India boasts the highest number of pharmaceutical manufacturing facilities that meet the standards of the US Food and Drug Administration (USFDA) and has 500 API producers, which account for approximately 8% of the global active pharmaceutical ingredient (API) market. Lupin is a major provider of anti-TB API to several leading global institutions and is among the top five pharmaceutical brands in India, holding a 3.4% market share. 

Latest Stock News: 

Pharmaceutical giant Lupin experienced a surge in its share price on Thursday, February 13, 2025, with shares rising by 5.69% to reach an intraday high of Rs 2,140.20. This increase was driven by a strong performance in the third quarter of the financial year 2025 (Q3FY25). 

Lupin reported a remarkable 39.5% year-on-year increase in profit, which climbed to Rs 855.1 crore, up from Rs 613.1 crore in Q3FY24. Additionally, revenue rose by 11% to Rs 5,767.7 crore, compared to Rs 5,197.4 crore during the same period last year.  

The company’s operational performance was also impressive, with earnings before interest, taxes, depreciation, and amortization (EBITDA) soaring by 30.6% to Rs 1,355.8 crore. This led to an expansion in the EBITDA margin to 23.5%, an increase of 350 basis points from 20% a year ago. 

Segmental information: 

Lupin operates in multiple therapeutic and business segments: 

1. Generics: This segment is a key revenue driver, providing affordable off-patent medications across various therapeutic areas. 

2. Branded Formulations: Lupin has a strong presence in India and emerging markets, with leading brands in cardiovascular health, diabetes, respiratory conditions, gastroenterology, and women’s health. 

3. Speciality Pharmaceuticals: The focus here is on complex and niche therapies, particularly in the fields of neurology and respiratory diseases. 

4. Active Pharmaceutical Ingredients (APIs): Lupin manufactures APIs for both its formulations and for third-party clients around the world. 

5. Biotechnology and Biosimilars: The company is also engaged in the development of biosimilars, especially in oncology and immunology, as part of its long-term growth strategy. 

Subsidiary Information:   

Lupin Limited, a prominent global pharmaceutical company, has established a network of subsidiaries worldwide to enhance its market presence and operational capabilities. Below is an overview of some key subsidiaries: 

1. Lupin Pharmaceuticals, Inc., USA: Serves as Lupin’s U.S. subsidiary, focusing on the development and marketing of generic and branded pharmaceuticals in the American market. 

2. Pharma Dynamics (Proprietary) Ltd., South Africa: A leading generic pharmaceutical company in South Africa, offering a broad range of affordable medications. 

3. Hormosan Pharma GmbH, Germany: Specializes in generic pharmaceuticals, catering to various therapeutic areas within the German healthcare sector. 

4. Multicare Pharmaceuticals Philippines, Inc., Philippines: Focuses on providing high-quality pharmaceutical products to meet the healthcare needs of the Philippines. 

5. Generic Health Pty Ltd., Australia: Engages in the distribution of generic pharmaceutical products across Australia, ensuring accessibility to essential medications. 

6. Nanomi B.V., Netherlands: Involved in advanced drug delivery technologies, contributing to Lupin’s research and development efforts in innovative therapeutics. 

7. Lupin Atlantis Holdings SA, Switzerland: Manages Lupin’s operations and strategic initiatives within the European region. 

8. Lupin Healthcare (UK) Ltd., United Kingdom: Oversees the distribution and marketing of Lupin’s pharmaceutical products in the UK market. 

9. Lupin Pharma Canada Ltd., Canada: Dedicated to the development and commercialization of pharmaceutical products tailored for the Canadian healthcare system. 

10. Lupin Mexico S.A. de C.V., Mexico: Focuses on expanding Lupin’s footprint in the Mexican pharmaceutical market through a range of generic and branded products. 

11. Lupin Life Sciences Limited, India: Established to manage the generics business in India, aligning with Lupin’s strategic focus on the domestic market. 

12. Lupin Manufacturing Solutions Limited: Created to oversee the manufacturing, sale, export, and import of Active Pharmaceutical Ingredients (APIs) and intermediates, as well as to undertake contract development and manufacturing activities. 

Q3 Highlights: 

  • The company achieved a notable 39.5% year-over-year increase in profit, rising to Rs 855.1 crore in Q3 FY24 from Rs 613.1 crore in the same quarter last year.  
  • Revenue grew by 11% year-over-year, reaching Rs 5,767.7 crore compared to Rs 5,197.4 crore in Q3 FY24.  
  • EBITDA surged by 30.6%, climbing to Rs 1,355.8 crore and reflecting a strong operational performance.  
  • The EBITDA margin expanded to 23.5%, marking a 350 basis points increase from the previous year’s margin of 20%. 

Financial Summary: 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 5,197.00 5,768.00 16,642 20,011 
Expenses 4,159.00 4,412 14,921 16,211 
EBITDA 1,038.00 1,356 1,721.00 3,800.00 
OPM 20% 24% 10% 19% 
Other Income 29 54 151 131 
Net Profit 619.00 859.00 448 1,936 
NPM 11.91 14.89 2.69 9.67 
EPS 13.47 18.74 9.45 42.01 
Alkem Laboratories
Alkem Laboratories Q3 Results: Net Profit Rises 6% to ₹641 Cr, Revenue Growth Flat, Stock Drops 4%

Alkem Laboratories Limited: Overview 

Alkem Laboratories Limited is one of the major pharmaceutical companies in India located in Mumbai, India, which is well known for producing good quality generic and specialty drugs. The company engages in development, manufacturing, and marketing of pharmaceutical generics, formulations, and nutraceuticals in domestic as well as international markets. Alkem has 21 manufacturing facilities, out of which 19 are in India and 2 are in the United States, and it provides a wide range of products across various therapeutic segments, such as anti-infective, pain management, and vitamins. It markets its products to several international markets including the US, UK, Australia, Germany, South East Asia and Africa. India is a leading country in the pharmaceutical sector, known for producing cheap vaccines and drugs. Indian pharmaceutical industry is the third largest in the world and has been growing at a Compound Annual Growth Rate (CAGR) of 9.43% over the last nine years. The country also has the greatest number of US FDA-compliant pharmaceutical manufacturing facilities and there are about 500 Active Pharmaceutical Ingredient (API) manufacturers who contribute 8% of the global API market share. As of March 31, 2022, Alkem Laboratories Limited has 3.9% market share in the domestic formulation market thus making it the fifth-largest pharmaceutical company in India. 

Latest Stock News

Alkem Acquires Adroit Biomed Ltd.:  

Alkem Laboratories has acquired a 100% stake in Adroit Biomed Ltd., a pharmaceutical company specializing in skincare, for approximately ₹140 crore. This acquisition will help Alkem strengthen its presence in the dermatology and cosmetology segments. Alkem Chairman BN Singh stated, “The acquisition of Adroit will allow us to diversify our offerings, enhance market penetration, and solidify our position in dermatology and cosmetology.” 

Alkem Expands into Medical Technology: 

Alkem MedTech Private Limited, a wholly owned subsidiary of Alkem, is acquiring 100% equity in Bombay Ortho Industries Pvt. Ltd., a manufacturer of orthopaedic implants, for ₹147 crore. This move aligns with Alkem’s strategy to expand into the fast-growing MedTech sector in India. The transaction is expected to be completed by June 30, 2025, subject to regulatory approvals. Managing Director Sandeep Singh remarked, “The MedTech sector in India is growing rapidly, and the demand for implants is substantial. Through this acquisition, we aim to tap into the increasing need for high-quality medical devices.” 

Interim Dividend Announcement

Alkem Laboratories has declared an interim dividend of ₹37 per equity share (face value ₹2) for the financial year 2024-25. The dividend will be distributed on or after February 28, 2025. 

Segmental information

1. Anti-infectives 

Alkem is a market leader in India’s anti-infective therapy segment. This category accounts for 11.8% of the total Indian Pharmaceutical Market (IPM), and Alkem holds the No. 1 position with a broad range of medicines that combat various infections. 

2. Gastroenterology 

A key player in gastrointestinal therapies, Alkem operates in a segment that contributes 10% of the total IPM value, making it the third-largest therapy area in India. With lifestyle changes and increasing health concerns, this sector is expected to grow significantly over the next decade. Alkem currently holds a 7% market share in this category. 

3. Pain Management 

Alkem is a leading brand in pain management with popular products such as: 

  • Aldigesic P (Aceclofenac + Paracetamol) – Used for arthritis, sprains, and musculoskeletal pain 
  • Alkem Para 500mg – A paracetamol-based tablet for mild to moderate pain relief 
  • Alkem Piroxicam – Used for joint and muscle inflammation, including osteoarthritis and rheumatoid arthritis 

4. Vitamins & Minerals 

Alkem manufactures a variety of vitamin and mineral supplements, including calcium, vitamin D, vitamin B12, zinc, magnesium, and boron. Notable products include Hemfer XT (iron supplement) and GEMCAL D3 (calcium + vitamin D3). 

5. Neurology & CNS (Central Nervous System) 

Alkem is among the top 10 pharmaceutical companies in India for neurology and CNS therapies. Its products support treatments for Alzheimer’s, dementia, stroke, migraines, epilepsy, depression, and neuropathic pain. Over the past four years, Alkem has outperformed competitors in this segment, securing the 5th position in the Indian market (AIOCD MAT June 2019). 

6. Cardiology 

Alkem is an emerging player in the cardiology segment, operating through two divisions: Alkem Aspiria and Alkem Imperia. These focus on hypertension, dyslipidemia, and cardiovascular disease management. The company aims to become a key player in the cardiovascular sector by offering innovative treatment solutions. 

Subsidiaries and Global Presence

Domestic Subsidiaries (India) 

Wholly Owned Subsidiaries

  • Alkem Foundation – CSR and healthcare initiatives 
  • Alkem Medtech Private Limited – Medical devices & healthcare technology 
  • Alixer Nexgen Therapeutics Limited – Advanced pharmaceutical research 
  • Alkem Wellness Limited – Wellness & nutraceuticals 
  • Connect 2 Clinic Private Limited – Digital healthcare solutions 

Other Subsidiaries

  • Cachet Pharmaceuticals Pvt Ltd – Pharmaceutical formulations 
  • Indchemie Health Specialities Pvt Ltd – Specialty medicines 
  • Enzene Biosciences Limited – Biotechnology & biosimilars 

International Subsidiaries 

  • Europe: 
  • S & B Holdings S.a.r.l., Luxembourg – Global investment arm 
  • Ascend GmbH, Germany – European market operations 
  • Ascend Laboratories (UK) Ltd. – UK market expansion 
  • North & South America: 
  • Ascend Laboratories LLC, USA – US generic pharmaceutical market 
  • Ascend Laboratories Ltd., Canada – Canadian market operations 
  • Ascend Laboratories S.A.S, Colombia & Chile – Latin American expansion 
  • Asia-Pacific & Africa: 
  • Alkem Laboratories Korea Inc. – Expansion in South Korea 
  • Pharmacor Pty Limited, Australia – Australian market operations 
  • Pharmacor Ltd., Kenya – African pharmaceutical expansion 

Q3 Highlights

  • Net profit grew by 6% year-over-year, reaching ₹641 crore in Q3FY24, although it declined 9% from the previous quarter. 
  • Total income rose by 1.4% year-over-year to ₹3,467 crore, though it saw a 2.3% decline compared to the previous quarter. 
  • For the first nine months of FY25, net profit increased by over 25% YoY, reaching ₹1,893 crore. 
  • Following the earnings announcement, Alkem’s stock declined by 4%. 
  • The company has declared an interim dividend of ₹37 per equity share, payable on or after February 28, 2025. 

Financial Summary

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 3,324.00 3,374.00 11,599 12,668 
Expenses 2,616 2,615 9,977 10,419 
EBITDA 750 852 4037 2946 
OPM 21% 23% 14% 18% 
Other Income 42 93 101 186 
Net Profit 604 641 1,007 1,811 
NPM 18.17 19.00  14.30 
EPS 49.76 52.34 140.61 187.31 
Divi’s Laboratories Ltd Q3 FY25 Results
Divi’s Laboratories Ltd: Q3 FY25 Earnings, 64.5% Profit Growth & Stock Surge

Divi’s Laboratories Ltd: Overview 

Divi’s Laboratories Ltd., a major global API (Active Pharmaceutical Ingredients) manufacturer, was founded in 1990 as Divis Research Center, focusing initially on Research & Development. Today, it stands as one of the largest API companies worldwide, specializing in Intermediates, Nutraceuticals, and custom synthesis for innovator pharmaceuticals. It has a significant export-oriented business, with a presence in over 100 countries, supplying around 160 diverse products. Divi’s Laboratories Ltd. has achieved significant milestones in its growth and operations. In 2006-2008, the company developed Divi’s Pharma SEZ in Visakhapatnam for Nutraceuticals production, expanding its custom synthesis and Nutraceuticals portfolio to meet rising export demand. In 2011, Divi’s launched the DSN SEZ Unit at Visakhapatnam, increasing production capacity in generic and custom synthesis segments. From 2014-2018, Divi’s Laboratories passed multiple international regulatory inspections, including from the US FDA and COFEPRIS (Mexico), establishing EIR status for Unit-II, Visakhapatnam, which addressed previous regulatory concerns. These projects boosted Divi’s role in generic and big pharma markets. In line with its dedication to innovation and compliance, Divi’s has research centers in Hyderabad and at manufacturing sites, focusing on custom synthesis and process innovations. With two subsidiaries Divi’s continued investments in R&D, global regulatory compliance, and strategic expansion reinforce its commitment to high-quality pharmaceutical solutions, positioning it as a prominent player in the global API market.  

Latest Stock News 

The Phase 1 Green 3 project commenced its operations in January 2025, marking a significant milestone for Divi’s Laboratories by enhancing its production capacity. However, logistical challenges arose due to restrictions and disruptions in the Red Sea, forcing transportation to be rerouted through South Africa, which significantly increased logistics costs during the quarter. Despite these temporary cost pressures, freight expenses are anticipated to ease in the coming years, aided by Divi’s strong client relationships that have ensured customer retention. Material consumption remained stable, accounting for approximately 40% of the total revenue for the reporting period. Export revenue continued to be a key driver of overall earnings, contributing nearly 80% to total revenue, with shipments to Europe and the United States making up 87% of total exports. The company’s Nutraceuticals segment demonstrated notable growth, gaining market share within its category and generating revenue of ₹170 crore. Additionally, Divi’s Laboratories has an ongoing capital work in progress amounting to ₹1,170 crore, earmarked as capital expenditure for the current fiscal year, with ₹735 crore specifically allocated for the Kakinada project. The first phase of the Kakinada project is expected to be operational within six months, further strengthening Divi’s long-term growth prospects. As of December 31, 2024, the company reported a strong financial position with ₹3,659 crore in cash reserves. In the generics business, despite industry-wide pricing pressures, Divi’s has maintained stability through strategic pricing measures. Additionally, the company has implemented a well-structured inventory buffer, ensuring a diversified and uninterrupted supply chain that supports continued growth and resilience against market fluctuations. 

Business Segments

  • Generic APIs: Divi’s is a leading manufacturer of generic APIs, catering to pharmaceutical companies worldwide. It specializes in high-value APIs such as Naproxen, Dextromethorphan, Gabapentin, and Levetiracetam. The company’s backward integration and cost-efficient manufacturing give it an edge in this segment. 
  • Custom Synthesis: This segment involves contract manufacturing and development services (CDMO) for global pharmaceutical companies. Divi’s provides specialized synthesis solutions for patented molecules and intermediates used in drug development. 
  • Nutraceuticals: Divi’s has expanded into the growing Nutraceuticals market, offering high-quality carotenoids, vitamins, and other health supplements. The segment aligns with increasing consumer preference for wellness products and functional foods. 
  • Peptide and Oligonucleotide Manufacturing: With advancements in biotechnology, Divi’s has ventured into the synthesis of peptides and oligonucleotides, which are critical for new-generation therapeutics, including RNA-based drugs. 

Subsidiary Information

  • Divi’s Laboratories (USA) Inc.: Divi’s Laboratories (USA) Inc. serves as the company’s North American arm, focusing on marketing and distribution of pharmaceutical products across the United States and neighboring countries. This subsidiary ensures that Divi’s Laboratories can effectively cater to the significant demand in the U.S. market, which is one of the largest consumers of pharmaceuticals globally. 
  • Divi’s Laboratories Europe AG: Based in Switzerland, Divi’s Laboratories Europe AG is instrumental in managing the company’s operations across Europe. This subsidiary handles the marketing, distribution, and regulatory compliance of Divi’s products within European markets. The subsidiary’s strategic location in Switzerland provides logistical advantages and facilitates better engagement with European clients and regulatory bodies. 
  • Divi’s Nutraceuticals: Divi’s Nutraceuticals is a specialized division dedicated to the production and marketing of Nutraceuticals ingredients, including a wide range of carotenoids and vitamins. Divi’s Nutraceuticals emphasizes research and development to innovate and expand its product offerings, aligning with consumer trends towards preventive healthcare and nutrition. 
  • Divi’s Research and Development Centers: While not traditional subsidiaries, Divi’s multiple R&D centers across India function as specialized units focusing on the development of new processes, technologies, and products. The R&D centers ensure that Divi’s Laboratories remains at the forefront of pharmaceutical innovation, maintaining its competitive edge in the global market. 
  • Divi’s Manufacturing Units: Divi’s Laboratories operates several manufacturing units in India, each functioning as a critical component of its production infrastructure. These units are located in Telangana and Andhra Pradesh and are equipped with state-of-the-art technology to produce a wide range of APIs and intermediates. The manufacturing units adhere to stringent quality standards and have received approvals from major regulatory agencies worldwide.  

Q3 FY25 Earnings 

  • Revenue of ₹2297 crore in Q3 FY25 up by 23.9% YoY from ₹1855 crore in Q3 FY24.  
  • EBITDA of ₹730 crore in this quarter at a margin of 32% compared to 26% in Q3 FY24. 
  • Profit of ₹594 crore in this quarter compared to a ₹358 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 1855 2297 7757 7845 
Expenses 1366 1649 5397 5635 
EBITDA 489 730 2370 2210 
OPM 26% 32% 31% 28% 
Other Income 95 82 344 335 
Net Profit 358 594 1824 1600 
NPM 19.3% 25.9% 23.5% 20.4% 
EPS 13.5 22.4 68.7 60.3 
Sun Pharma Q3 FY25 Results
Sun Pharma Q3 FY25 Results: Revenue Up 10.5% YoY to ₹13,675 Cr, Profit Surges to ₹2,913 Cr

Sun Pharmaceuticals Industries Ltd: Overview 

Sun Pharmaceutical Industries Ltd. is the largest pharmaceutical company in India and one of the leading specialty generic drug manufacturers globally. It operates across over 100 markets, with a strong presence in the U.S., India, Emerging Markets, and Western Europe. The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. The company’s product portfolio includes branded generics, complex generics, active pharmaceutical ingredients (APIs), and specialty drugs, particularly in dermatology, ophthalmology, and oncology. With an extensive R&D focus, Sun Pharma has consistently expanded its specialty drug pipeline, leveraging both organic growth and strategic acquisitions. It produces a comprehensive and diverse portfolio of generic and specialty medicines targeting wide spectrum of chronic and acute treatments. The global pharmaceutical industry is experiencing strong growth driven by rising healthcare expenditures, increased chronic disease prevalence, and higher demand for specialty medications. India remains a key player in the global generic drug industry, supplying over 20% of global generics by volume. Additionally, Sun Pharma is capitalizing on regulatory approvals, biosimilars opportunities, and increased focus on high-margin specialty drugs, positioning itself for sustainable long-term growth. 

Latest Stock News 

India’s formulation sales reached ₹43,004 million, marking a 13.8% increase. US formulation sales were USD 474 million, showing a slight decline of 0.7%. Global Specialty sales amounted to USD 370 million, which includes USD 45 million in milestone revenues. Excluding these milestones, Global Specialty sales grew by 17.5%. These sales, excluding milestones, represented 21% of total Q3FY25 sales. Formulation sales in emerging markets reached USD 277 million, up 10.1%, while sales in the rest of the world rose by 21% to USD 259 million. The company’s R&D investments for the quarter stood at ₹8,450 million, up from ₹8,245 million in Q3FY24. According to the SMSRC (July-Oct 2024) report, the company is ranked No.1 by prescriptions across 12 doctor categories. In Q3FY25, the company launched 12 new products in the Indian market. In the US, formulation sales were USD 474 million for Q3FY25, down 0.7% compared to the same quarter last year, accounting for about 30% of the total consolidated sales. For the first nine months of the fiscal year, sales amounted to USD 1,457 million, reflecting a 5.7% increase. The R&D pipeline includes 7 novel entities undergoing clinical trials. The company offers a comprehensive product portfolio in the US market, with approved ANDAs for 541 products and 109 ANDAs pending US FDA approval, including 28 tentative approvals. Additionally, there are 51 approved NDAs, with 13 NDAs awaiting US FDA approval. During the quarter, 6 ANDA filings were made, and 2 ANDA approvals were received. Upcoming developments include Phase 3 topline data for Ilumya in psoriatic arthritis expected in H2CY25, and the approval of Leqselvi for severe alopecia areata in the US. 

Business Segments

  • India Business: Contributing around 32% of total revenue, Sun Pharma is the largest pharmaceutical company in India with a robust branded generics portfolio, covering therapies such as cardiology, dermatology, ophthalmology, and diabetes. The company continues to launch innovative first-to-market formulations and expand its domestic reach. 
  • U.S. Business: The largest revenue contributor, accounting for approximately 30% of total sales. Sun Pharma has a strong pipeline of complex generics, specialty drugs, and biosimilars, with key brands including Ilumya (psoriasis), Cequa (dry eye), and Odomzo (skin cancer). The U.S. generics market remains competitive, but Sun Pharma’s differentiated portfolio provides an edge. 
  • Emerging Markets (EM): This segment contributes around 18% of revenue, covering Asia, Latin America, and Russia/CIS regions. Sun Pharma continues to strengthen its branded generics presence, leveraging its local partnerships, strong distribution network, and diversified product pipeline. 
  • Rest of the World (ROW): Comprising markets in Western Europe, Canada, and Australia, this segment contributes nearly 14% of revenue. The company focuses on branded generics and specialty drug launches in key developed markets. 
  • Active Pharmaceutical Ingredients (APIs): A crucial segment, supplying APIs both internally for formulations and externally to third parties. Sun Pharma’s API business provides a competitive cost advantage, backed by state-of-the-art manufacturing and backward integration. 

Subsidiary Information

  • Taro Pharmaceuticals: Taro Pharmaceuticals is a key subsidiary of Sun Pharma, operating across the United States, Canada, and Israel, with a strong focus on dermatology and niche generic drugs. The company has established itself as a leader in the development and manufacturing of topical formulations, which include creams, ointments, and gels used in the treatment of various skin conditions. Taro’s specialization in dermatology has allowed it to build a robust portfolio of high-margin specialty products. 
  • Ranbaxy Laboratories: Sun Pharma acquired Ranbaxy Laboratories in 2015, a strategic move that significantly strengthened its global generics portfolio. Ranbaxy had a well-established presence in India and Emerging Markets, bringing with it an extensive product range and a wide distribution network. The integration of Ranbaxy into Sun Pharma’s operations led to substantial improvements in research and development (R&D) capabilities, enabling the company to develop and launch high-quality, affordable generic medicines across multiple geographies. 
  • Poland’s Polpharma: Polpharma, a leading pharmaceutical company based in Eastern Europe, plays a crucial role in strengthening Sun Pharma’s position in the CIS (Commonwealth of Independent States) and European branded generics market. With a strong focus on branded generics, Polpharma provides Sun Pharma with access to an extensive product portfolio and a well-established distribution network across multiple European countries. 
  • Dusa Pharmaceuticals: Dusa Pharmaceuticals is a specialized subsidiary that focuses on photodynamic therapy (PDT) for dermatological treatments, reinforcing Sun Pharma’s position in the high-value specialty pharmaceutical segment. Dusa’s innovative light-activated drug treatments are widely used for various skin-related disorders, offering patients advanced therapeutic options.  
  • Sun Pharma Advanced Research Company (SPARC): Sun Pharma Advanced Research Company (SPARC) serves as the dedicated research and development (R&D) arm of Sun Pharma, focusing on new drug discovery, innovative drug delivery systems, and specialty pharmaceuticals. By continuously investing in cutting-edge research, SPARC enhances Sun Pharma’s long-term growth strategy, reinforcing its position as a global leader in the pharmaceutical industry. 

Q3 FY25 Earnings 

  • Revenue of ₹13675 crore in Q3 FY25 up by 10.5% YoY from ₹12381 crore in Q3 FY24.  
  • EBITDA of ₹4009 crore in this quarter at a margin of 29% compared to 28% in Q3 FY24. 
  • Profit of ₹2913 crore in this quarter compared to a ₹2516 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 12381 13675 43886 48497 
Expenses 8904 9666 32235 35479 
EBITDA 3477 4009 11650 13018 
OPM 28% 29% 27% 27% 
Other Income 180 149 459 865 
Net Profit 2561 2913 8513 9610 
NPM 20.6% 21.3% 19.4% 19.8% 
EPS 10.5 12.1 35.3 39.9 
Cipla Ltd Q3 FY25
Cipla Ltd Q3 FY25: Net Profit Soars 49% to ₹1,571 Cr, Strong Growth Across Segments

Cipla Ltd: Overview 

Cipla Ltd. is a leading global pharmaceutical company headquartered in India, known for its wide-ranging portfolio of affordable and high-quality medicines. The company operates across several therapeutic areas, including respiratory, cardiovascular, oncology, anti-infectives, and dermatology, with a strong focus on both branded prescription drugs and generic medicines. Cipla’s products cater to diverse markets, from emerging economies to developed nations, ensuring broad accessibility to essential healthcare solutions. The company is also actively expanding its presence in the consumer health sector, offering over-the-counter products and wellness solutions. 

The global increase in life expectancy, along with better healthcare access, is driving demand for pharmaceutical products, particularly those addressing chronic conditions and lifestyle diseases. Cipla has a robust global footprint, with subsidiaries in over 40 countries, including the United States, South Africa, and Uganda, among others. In addition to its manufacturing facilities in India, Cipla has invested in cutting-edge research and development to address critical health challenges, particularly in the areas of HIV/AIDS and malaria. Emerging markets represent a significant growth opportunity due to growing healthcare needs. India, Africa, and Latin America are seeing increased demand for affordable medicines, and Cipla has a strong presence in these regions. Operating in the highly competitive pharmaceutical industry, Cipla remains committed to providing sustainable healthcare solutions through innovation, affordability, and access to life-saving treatments. 

Latest Stock News 

In the U.S. Albuterol Generic market, Cipla’s Albuterol ranked #1, with its market share increasing to 21% during the quarter. However, Lanreotide supply issues impacted overall sales. As of December 2024, the company reported a total debt of ₹466 crores and a cash balance of ₹9413 crores. In the branded prescription segment, Cipla maintained its #2 market rank in the overall Chronic category, with an improved chronic mix of 61.5%. Key therapies like Respiratory, Urology, and Acute have been outpacing the market, with Urology achieving a 16% YoY market growth and maintaining its #2 rank. In Trade Generics, Cipla’s business is back on a growth trajectory, with two brands generating over INR 100 crore in TTM revenue and five brands generating INR 50 crore to INR 100 crore.  

Additionally, 18 new products were launched in 9M FY25. The Consumer Health segment also saw robust growth, with anchor and transitioned brands continuing to perform well. The company sustained a positive EBITDA trajectory, and key products such as Nicotex, Omnigel, and Cipladine ranked #1 in their respective markets. Furthermore, five new brands joined the market with revenue over INR 100 crore YoY. Cipla also received various generic drug approvals, including Phytonadione injectable 1mg/0.5ml, Esomeprazole granules 2.5mg/5mg, and Potassium Phosphates Injection USP. Additionally, Cipla’s Goa facility has been classified as ‘VAI’ (Voluntary Action Indicated) by the USFDA. 

Business Segments 

  • Branded Prescription: This is the primary segment of Cipla, consisting of prescription medicines that are sold under the Cipla brand to healthcare providers and patients. It covers a wide range of therapeutic areas, such as respiratory, cardiovascular, oncology, dermatology, and anti-infectives. The company’s branded products are well-established in several markets, including India, South Africa, and other emerging markets. They include both innovative drugs and generic formulations that provide affordable treatments. 
  • Trade Generics: This segment includes Cipla’s generic pharmaceutical products that are sold under non-branded names or as generic versions of branded medicines. Trade generics offer a more cost-effective option compared to branded prescription drugs. Cipla’s trade generics are available in several global markets, including India, where generics play a significant role due to high demand for affordable medicines. 
  • Consumer Health: Cipla’s Consumer Health segment is focused on non-prescription products, including over-the-counter (OTC) medicines and wellness products. These typically include treatments for common health issues like cough and cold, pain relief, digestive health, and dermatological needs. The company offers a wide range of vitamins, minerals, and supplements (VMS) in this category, targeting the growing wellness trend. It also includes products designed for specific consumer needs, like personal care products. 

Subsidiary Information 

  • Cipla Health Ltd: This subsidiary handles Cipla’s consumer health business, including over-the-counter (OTC) medicines and wellness products. Cipla Health focuses on non-prescription products like dietary supplements, personal care items, and vitamins, aiming to cater to the growing demand for health-conscious consumers. 
  • Cipla USA Inc.: Cipla USA is responsible for the distribution and marketing of Cipla’s generic and branded pharmaceutical products in the U.S. market. It plays a critical role in bringing Cipla’s generics to the U.S. and includes products in areas such as respiratory care, oncology, and central nervous system treatments. 
  • Cipla Europe Ltd: Cipla Europe focuses on the development and commercialization of Cipla’s products in European markets. The subsidiary supports Cipla’s growth in the European generic pharmaceuticals sector and markets products across various therapeutic areas, including oncology, respiratory, and cardiology. 
  • Cipla South Africa Ltd (Cipla Medpro): Cipla South Africa is one of Cipla’s most significant subsidiaries in Africa. The company provides affordable healthcare solutions across various therapeutic segments, including HIV/AIDS, oncology, and respiratory care, while also focusing on improving access to medicines across the continent. 

Q3 FY25 Earnings 

  • Revenue of ₹7073 crore in Q3 FY25 up by 7.01% YoY from ₹6604 crore in Q3 FY24.  
  • EBITDA of ₹1989 crore in this quarter at a margin of 28% compared to 26% in Q3 FY24. 
  • Profit of ₹1575 crore in this quarter compared to a ₹1068 crore profit in Q3 FY24. 

Financial Summary 

Amount in ₹ Cr Q3 FY24 Q3 FY25 FY23 FY24 
Revenue 6604 7073 22753 25774 
Expenses 4856 5084 17726 19483 
EBITDA 1748 1989 5027 6291 
OPM 26% 28% 22% 24% 
Other Income -10 222 293 552 
Net Profit 1068 1575 2833 4154 
NPM 16.2% 22.3% 12.5% 16.1% 
EPS 13.08 19.5 34.7 51.1